CG Oncology’s (CGON) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.

A number of other equities analysts have also recently issued reports on CGON. Bank of America reiterated a “buy” rating and set a $65.00 target price on shares of CG Oncology in a report on Tuesday, October 8th. Roth Capital upgraded shares of CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. Royal Bank of Canada started coverage on CG Oncology in a research note on Monday, September 23rd. They issued an “outperform” rating and a $66.00 price target for the company. Finally, UBS Group assumed coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 target price for the company. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, CG Oncology presently has a consensus rating of “Buy” and an average price target of $63.88.

CG Oncology Trading Down 6.8 %

NASDAQ:CGON opened at $36.98 on Tuesday. The business’s 50-day simple moving average is $36.87 and its 200-day simple moving average is $34.80. CG Oncology has a fifty-two week low of $25.77 and a fifty-two week high of $50.23.

Insider Activity at CG Oncology

In related news, Director Hong Fang Song sold 650,455 shares of CG Oncology stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the completion of the sale, the director now directly owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Institutional Investors Weigh In On CG Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in CG Oncology by 114.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock worth $14,325,000 after purchasing an additional 202,262 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of CG Oncology by 4.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 279,945 shares of the company’s stock valued at $10,562,000 after buying an additional 13,158 shares during the period. Los Angeles Capital Management LLC acquired a new stake in CG Oncology during the third quarter worth approximately $832,000. TimesSquare Capital Management LLC increased its stake in CG Oncology by 27.4% during the 3rd quarter. TimesSquare Capital Management LLC now owns 437,069 shares of the company’s stock worth $16,491,000 after acquiring an additional 94,010 shares during the period. Finally, Amalgamated Bank raised its holdings in CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after acquiring an additional 840 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.